Patents by Inventor Bernard Allet

Bernard Allet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5487984
    Abstract: A process of producing mammalian tumor necrosis factors (TNF) and TNF-like polypeptides by culturing eukaryotic or prokaryotic hosts transformed with DNA sequences encoding those polypeptides. A process for purifying TNF-like polypeptides using an anion exchanger. The TNFs and TNF-like polypeptides produced by the processes of this invention, and compositions and methods utilizing those TNFs and TNF-like polypeptides, are useful in anticancer, antitumor and antimalarial therapies. They are also useful together with interferon therapy, chemotherapy in anticancer and antitumor therapies, and in combination with actinomycin D in the treatment of tumor-bearing mammals.
    Type: Grant
    Filed: December 20, 1985
    Date of Patent: January 30, 1996
    Assignee: Biogen, Inc.
    Inventors: Bernard Allet, Eric H. Kawashima
  • Patent number: 5182196
    Abstract: Recombinant DNA molecules comprising DNA sequences derived from bacteriophage T4 that are useful in expressing desired polypeptides in unexpectedly high yields, hosts and expression systems comprising such recombinant DNA molecules and methods for expressing desired polypeptides in high yields by the utilization of such hosts and expression systems.
    Type: Grant
    Filed: June 27, 1989
    Date of Patent: January 26, 1993
    Assignee: Biogen, Inc.
    Inventors: Bernard Allet, Eric H. Kawashima
  • Patent number: 5004689
    Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of gamma interferon. The genes coding for these polypeptides and methods of making and using these DNA sequences, molecules, hosts, genes and polypeptides are disclosed. The DNA sequences of this invention are further characterized by expression control sequences which permit the production of gamma interferon in high yields. More particularly, these expression control sequences comprise the .lambda. P.sub.L promoter, and more preferably, a trp-derived expression control sequence containing the sequence ATCGATACT between the Shine-Dalgarno sequence and the translational start signal.
    Type: Grant
    Filed: March 27, 1987
    Date of Patent: April 2, 1991
    Assignee: Biogen, Massachusetts
    Inventors: Walter C. Fiers, Bernard Allet